Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg

Author:Tepper, Stewart   Abraham, Lucy   Bushmakin, Andrew   Cappelleri, Joseph   Fullerton, Terence   Yang, Jiyue   Lipton, Richard   

Session Name:P9: Headache: Advances in CGRP Inhibitors and Migraine 2  

Topic:Headache  

Program Number:P9.005  

Author Institution:New England Institute for Neurology and Headache, Stamford, CT  Pfizer R&D UK Ltd, Tadworth, United Kingdom  Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  Montefiore Headache Center and the Albert Einstein College of Medicine, New York, NY  

A Phase 4, Open-label Study Evaluating the Safety and Tolerability of Once Daily Rimegepant for Episodic Migraine Prevention

Author:Antinew, Jeremias   Fountaine, Robert   Loprinzo, Vittorio   Straghan, Esther   Fullerton, Terence   

Session Name:P11: Emerging Science  

Topic:Headache  

Program Number:P11.008  

Author Institution:Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  Pfizer Ltd., Surrey, United Kingdom